Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

Unbundling versus Best Ex

So, the September date looms for ESMA’s final clarification on unbundling. What seems evident is that payment for research with trading commissions is definitely going to be out. What seems less clear, though, is what can still be bundled into the definition of ‘execution’ and therefore still be paid for in commission dollars. Presumably, post-trade TCA services are included as they could just be thought of as a fancy form of invoice or, in the case of pre- or real-time analytics, as a mechanism that allows customers to monitor what is going on. But what about market data, or the screen and other technical paraphernalia involved in displaying those analytics? What about allocations and trade affirmations that finalise the execution process prior to clearing?

ESMA seems to distinguish between the investment decision (what to trade and why) and the execution decision (where to trade and when). Taken literally then, anything that helps a buy-side decide how to trade an order could legitimately be paid for in commission dollars. But this seems to fly in the face of unbundling’s twin brother – best execution. Surely each buy-side will need to independently assess the execution capabilities of its brokers?

Whilst all the focus has been on how payment for research is going to work in an unbundled world, maybe the smart thing to do is think about what can still be included.

Comments
One Response to “Unbundling versus Best Ex”
  1. Interestingly, the separation between investment and execution decision is discussed by ESMA when looking into the transaction reporting requirements under MIFID II. This looks like just another example of unintended consequences.

Leave a comment

Copyright © 2018 Fidessa Group Holdings Limited. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa Group Holdings Limited.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.